Radon and lung cancer: a cost-effectiveness analysis

Am J Public Health. 1999 Mar;89(3):351-7. doi: 10.2105/ajph.89.3.351.

Abstract

Objectives: This study examined the cost-effectiveness of general and targeted strategies for residential radon testing and mitigation in the United States.

Methods: A decision-tree model was used to perform a cost-effectiveness analysis of preventing radon-associated deaths from lung cancer.

Results: For a radon threshold of 4 pCi/L, the estimated costs to prevent 1 lung cancer death are about $3 million (154 lung cancer deaths prevented), or $480,000 per life-year saved, based on universal radon screening and mitigation, and about $2 million (104 lung cancer deaths prevented), or $330,000 per life-year saved, if testing and mitigation are confined to geographic areas at high risk for radon exposure. For mitigation undertaken after a single screening test and after a second confirmatory test, the estimated costs are about $920,000 and $520,000, respectively, to prevent a lung cancer death with universal screening and $130,000 and $80,000 per life-year for high risk screening. The numbers of preventable lung cancer deaths are 811 and 527 for universal and targeted approaches, respectively.

Conclusions: These data suggest possible alternatives to current recommendations.

MeSH terms

  • Aged
  • Air Pollutants, Radioactive / adverse effects*
  • Cost-Benefit Analysis
  • Decision Trees*
  • Female
  • Housing*
  • Humans
  • Lung Neoplasms / chemically induced*
  • Lung Neoplasms / economics
  • Lung Neoplasms / mortality
  • Lung Neoplasms / prevention & control*
  • Male
  • Mass Screening / economics
  • Mass Screening / methods*
  • Radiation Monitoring / economics
  • Radiation Monitoring / methods*
  • Radon / adverse effects*
  • Sensitivity and Specificity
  • United States / epidemiology
  • United States Environmental Protection Agency
  • Value of Life

Substances

  • Air Pollutants, Radioactive
  • Radon